Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection.

Abstract

In this real-world cohort, 49% of patients stopped boceprevir-based hepatitis C therapy early, with only 20% stopping due to treatment futility. Having more comorbidities was significantly associated with early discontinuation. Tolerability of boceprevir-based regimens may be substantially worse than reported in clinical trials, particularly for patients with comorbidities.

• Authors: A Majid, J McAninch, D J Morgan, S S El Kamary, M Zhan, L Kapelusznik, R Talwani
• Journal: Journal of viral hepatitis (J Viral Hepat) Vol. 21 Issue 8 Pg. 585-9 (Aug 2014) ISSN: 1365-2893 [Electronic] England
• PMID: 24224781 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
• Copyright: © 2013 John Wiley & Sons Ltd.

Chemical References

• Antiviral Agents
• N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
• Proline

Topics

• Adult
• Aged
• Antiviral Agents (adverse effects, therapeutic use)
• Cohort Studies
• Hepatitis C, Chronic (drug therapy)
• Humans
• Male
• Middle Aged
• Prognosis
• Proline (adverse effects, analogs & derivatives, therapeutic use)
• Retrospective Studies
• Withholding Treatment